middle.news
Neurotech Secures US Patent Allowances for NTI164, Extending Protection to 2042
9:35am on Thursday 2nd of July, 2026 AEST
•
Healthcare
Read Story
Neurotech Secures US Patent Allowances for NTI164, Extending Protection to 2042
9:35am on Thursday 2nd of July, 2026 AEST
Key Points
USPTO issues Notices of Allowance for two NTI164 patents
Patents cover neuroinflammation reduction and autism treatment methods
Protection expected through to 2042 upon patent grants
NTI164 currently in Phase 3 clinical trials for paediatric ASD
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neurotech International (ASX:NTI)
OPEN ARTICLE